- Home
- OVV vs INCY Comparison
OVV vs INCY Comparison
Compare OVV & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OVV
- INCY
- Stock Information
- Founded
- OVV 2020
- INCY 1991
- Country
- OVV United States
- INCY United States
- Employees
- OVV N/A
- INCY N/A
- Industry
- OVV Oil & Gas Production
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- OVV Energy
- INCY Health Care
- Exchange
- OVV Nasdaq
- INCY Nasdaq
- Market Cap
- OVV 11.9B
- INCY 13.3B
- IPO Year
- OVV N/A
- INCY 1993
- Fundamental
- Price
- OVV $45.40
- INCY $73.47
- Analyst Decision
- OVV Buy
- INCY Buy
- Analyst Count
- OVV 17
- INCY 19
- Target Price
- OVV $56.19
- INCY $75.44
- AVG Volume (30 Days)
- OVV 2.8M
- INCY 1.6M
- Earning Date
- OVV 02-26-2025
- INCY 02-10-2025
- Dividend Yield
- OVV 2.64%
- INCY N/A
- EPS Growth
- OVV N/A
- INCY N/A
- EPS
- OVV 7.54
- INCY 0.15
- Revenue
- OVV $9,562,000,000.00
- INCY $4,075,860,000.00
- Revenue This Year
- OVV N/A
- INCY $16.00
- Revenue Next Year
- OVV N/A
- INCY $10.47
- P/E Ratio
- OVV $6.02
- INCY $494.37
- Revenue Growth
- OVV N/A
- INCY 12.94
- 52 Week Low
- OVV $36.91
- INCY $50.35
- 52 Week High
- OVV $55.95
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- OVV 68.80
- INCY 57.44
- Support Level
- OVV $44.90
- INCY $71.72
- Resistance Level
- OVV $46.17
- INCY $73.83
- Average True Range (ATR)
- OVV 1.14
- INCY 1.85
- MACD
- OVV 0.59
- INCY 0.37
- Stochastic Oscillator
- OVV 89.50
- INCY 78.61
About OVV Ovintiv Inc. (DE)
Ovintiv is a North American oil and natural gas exploration and production company. It focuses on the exploration and development of oil, NGLs, and natural gas reserves. The company has three segments: USA Operations, Canadian Operations, and Market Optimization.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.